Ligand id: 9173

Name: rebastinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 123.06
Molecular weight 553.22
XLogP 5.68
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Compound class Synthetic organic
International Nonproprietary Names
INN number INN
9685 rebastinib
DCC 2036 | DCC-2036 | DP-1919
Database Links
CAS Registry No. 1020172-07-9 (source: WHO INN record)
ChEMBL Ligand CHEMBL1738757
GtoPdb PubChem SID 315661256
PubChem CID 25066467
RCSB PDB Ligand 919
Search Google for chemical match using the InChIKey WVXNSAVVKYZVOE-UHFFFAOYSA-N
Search Google for chemicals with the same backbone WVXNSAVVKYZVOE
Search PubMed clinical trials rebastinib
Search PubMed titles rebastinib
Search PubMed titles/abstracts rebastinib
Search UniChem for chemical match using the InChIKey WVXNSAVVKYZVOE-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone WVXNSAVVKYZVOE
SynPHARM 83605 (in complex with ABL proto-oncogene 1, non-receptor tyrosine kinase)
Rebastinib is an investigational kinase inhibitor, with activity against FLT3-ITD, TIE2, KDR, LYN, BCR-ABL and TRKA kinases. Yes1 inhibition is reported in [4]. This compound has been termed a switch-control inhibitor as it binds to residues Arg386/Glu282 which ABL1 uses to switch between inactive and active conformations [1-2]. Rebastinib inhibits native and phosphphorylated ABL by inducing a type II inactive conformation [1].
It is one of the compounds claimed in patent WO2008046003 [5] and subsequent related patent applications. Rebastinib appears to be Example 1, whilst acknowledging the limitations and complexities applied in compound naming and structure provision in the patent document.